Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Parathyroid hormone update.

Kendal L Hamann1, Nancy E Lane

  • 1Division of Endocrinology, Clinical Nutrition, and Vascular Medicine, University of California Davis Medical Center, 4150 V Street, Suite G400, Sacramento, CA 95817, USA. kendal.hamann@ucdmc.ucdavis.edu

Rheumatic Diseases Clinics of North America
|February 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep learning-based quantification of knee effusion-synovitis volume on MRI - Technique development and validation.

Osteoarthritis and cartilage·2026
Same author

Elevated Serum CXCL9 Levels Are Associated with Greater Frailty Risk in Older Women.

Endocrinology and metabolism (Seoul, Korea)·2026
Same author

Association between central obesity and MRI-based biomarkers of knee osteoarthritis independent of BMI: A cross-sectional study from the Osteoarthritis Initiative database.

Osteoarthritis and cartilage open·2026
Same author

Sex- and site-specific associations between hemoglobin levels and cortical bone structure and microarchitecture in older adults.

Bone·2026
Same author

Transcriptomic Profiling in Skeletal Muscle Identifies Associations With Knee Osteoarthritis: the Study of Muscle, Mobility and Aging (SOMMA).

medRxiv : the preprint server for health sciences·2026
Same author

Greater recalled pain and movement-evoked pain are associated with longer 400-m walk and repeat stair climb timein older adults: the study of muscle, mobility, and aging.

GeroScience·2026
Same journal

Bridging the Divide in Global Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence and Social Determinants of Health.

Rheumatic diseases clinics of North America·2026
Same journal

Updates in Ultrasound in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Health Systems Strengthening to Promote Access to Care for Rheumatic and Musculoskeletal Diseases Globally.

Rheumatic diseases clinics of North America·2026
See all related articles

Parathyroid hormone (PTH) offers a new anabolic treatment for osteoporosis in men and women, effectively increasing bone mineral density and reducing fractures. While safe for two years, further research is needed for longer-term use and optimal combination therapies.

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Osteoporosis is a significant health concern, particularly in postmenopausal women and hypogonadal men.
  • Current treatments primarily focus on antiresorptive mechanisms.
  • There is a need for novel anabolic agents to improve bone metabolism and reduce fracture risk.

Purpose of the Study:

  • To evaluate parathyroid hormone (PTH) as a novel anabolic treatment for osteoporosis.
  • To assess the efficacy of PTH in increasing bone mineral density (BMD) and reducing fractures.
  • To explore the safety and optimal use of PTH, including combination and sequential therapies.

Main Methods:

  • Review of numerous clinical trials investigating PTH in men and women with osteoporosis.

Related Experiment Videos

  • Analysis of data on changes in trabecular and cortical BMD.
  • Evaluation of fracture reduction rates (vertebral and nonvertebral).
  • Assessment of safety data for up to 2 years of PTH use.
  • Comparison of PTH monotherapy, combined therapy with bisphosphonates, and sequential therapy.

    • Main Results:

    • PTH demonstrated significant increases in both trabecular and cortical BMD, with greater effects on trabecular bone.
    • Clinical trials showed a reduction in vertebral and nonvertebral fractures in postmenopausal women.
    • PTH appears safe for use up to 2 years.
    • Sequential therapy with PTH followed by bisphosphonates yielded greater BMD gains than combined therapy or antiresorptive monotherapy.

    Conclusions:

    • Parathyroid hormone (PTH) represents a new class of anabolic medication for osteoporosis.
    • PTH effectively increases BMD and reduces fracture risk in relevant patient populations.
    • Optimal therapeutic strategies may involve sequential administration of PTH and bisphosphonates, with further research needed for long-term safety and efficacy.